{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:52:09Z","timestamp":1789159929317,"version":"build-2803163510"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) and vascular dementia (VaD) are the two most common types of neurodegenerative dementia among the elderly with similar symptoms of cognitive decline and overlapping neuropsychological profiles. Biological markers to distinguish patients with VaD from AD would be very useful. We aimed to investigate the expression of blood-brain barrier (BBB)-related blood-borne factors of soluble low-density lipoprotein receptor-related protein 1 (sLRP1), cyclophilin A (CyPA), and matrix metalloproteinase 9 (MMP9) and its correlation with cognitive function between patients with AD and VaD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Plasma levels of sLRP1, CyPA, and MMP9 were analyzed in 26 patients with AD, 27 patients with VaD, and 27 normal controls (NCs). Spearman\u2019s rank correlation analysis was used to explore the relationships among biomarker levels, cognitive function, and imaging references. Receiver operating characteristic (ROC) curve analysis was used to discriminate the diagnosis of AD and VaD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among these BBB-related factors, plasma CyPA levels in the VaD group were significantly higher than that in the AD group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). Plasma sLRP1 levels presented an increasing trend in VaD while maintaining slightly low levels in patients with AD (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Plasma MMP9 in different diagnostic groups displayed the following trend: VaD group &amp;gt; AD group &amp;gt; NC group, but the difference was not statistically significant (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Furthermore, plasma sLRP1 levels were positively related to MoCA scores, and plasma CyPA levels were significantly correlated with MTA scores (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) in the AD group. Plasma MMP9 levels were negatively correlated with MoCA scores (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) in the VaD groups. No significant correlation was detected between the other factors and different cognitive scores (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). ROC analysis showed a good preference of plasma CyPA [AUC = 0.725, 95% CI (0.586\u20130.865); <jats:italic>p<\/jats:italic> = 0.0064] in diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The plasma CyPA level is a reference index when distinguishing between an AD and subcortical ischemic vascular dementia (SIVD) diagnosis. Blood-derived factors associated with the BBB may provide new insights into the differential diagnosis of neurodegenerative dementia and warrant further investigation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2022.949129","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:08:44Z","timestamp":1659942524000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Contribution of blood-brain barrier-related blood-borne factors for Alzheimer\u2019s disease vs. vascular dementia diagnosis: A pilot study"],"prefix":"10.3389","volume":"16","author":[{"given":"Min","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1161\/01.Str.0000127420.10990.76","article-title":"Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.","volume":"35","author":"Adair","year":"2004","journal-title":"Stroke"},{"key":"B2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mcn.2013.06.004","article-title":"Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.","volume":"56","author":"Bachmeier","year":"2013","journal-title":"Mol. Cell. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/wnl.54.6.1304","article-title":"MRI volumetric study of dementia with Lewy bodies: A comparison with AD and vascular dementia.","volume":"54","author":"Barber","year":"2000","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/strokeaha.109.570515","article-title":"Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9.","volume":"41","author":"Barr","year":"2010","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.neuron.2010.09.043","article-title":"Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging.","volume":"68","author":"Bell","year":"2010","journal-title":"Neuron"},{"key":"B6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.","volume":"485","author":"Bell","year":"2012","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3233\/jad-170680","article-title":"Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer\u2019s Disease Diagnosis.","volume":"62","author":"Bjerke","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1089\/rej.2019.2182","article-title":"The Neuroprotective Effects of Danggui-Shaoyao San on Vascular Cognitive Impairment: Involvement of the Role of the Low-Density Lipoprotein Receptor-Related Protein.","volume":"23","author":"Cai","year":"2020","journal-title":"Rejuvenation Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/jad-180098","article-title":"Role of Blood-Brain Barrier in Alzheimer\u2019s Disease.","volume":"63","author":"Cai","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/strokeaha.110.600825","article-title":"Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.","volume":"42","author":"Candelario-Jalil","year":"2011","journal-title":"Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.neurobiolaging.2014.03.009","article-title":"Medial temporal atrophy in early and late-onset Alzheimer\u2019s disease.","volume":"35","author":"Cavedo","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/kjm2.12143","article-title":"Association of cyclophilin A level and pulse pressure in predicting recurrence of cerebral infarction.","volume":"36","author":"Chang","year":"2020","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/1567202615666180516120959","article-title":"Cyclophilin A: A Predictive Biomarker of Carotid Stenosis in Cerebral Ischemic Stroke.","volume":"15","author":"Chang","year":"2018","journal-title":"Curr. Neurovasc. Res."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11050740","article-title":"Relationship between Brain Tissue Changes and Blood Biomarkers of Cyclophilin A, Heme Oxygenase-1, and Inositol-Requiring Enzyme 1 in Patients with Alzheimer\u2019s Disease.","volume":"11","author":"Choi","year":"2021","journal-title":"Diagnostics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","article-title":"RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.","volume":"9","author":"Deane","year":"2003","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2174\/138161208784705487","article-title":"The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer\u2019s disease.","volume":"14","author":"Deane","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","article-title":"LRP\/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.","volume":"43","author":"Deane","year":"2004","journal-title":"Neuron"},{"key":"B18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00401-006-0115-3","article-title":"RAGE, LRP-1, and amyloid-beta protein in Alzheimer\u2019s disease.","volume":"112","author":"Donahue","year":"2006","journal-title":"Acta Neuropathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.2147\/dmso.S260293","article-title":"Cyclophilin A (CyPA) as a Novel Biomarker for Early Detection of Diabetic Nephropathy in an Animal Model.","volume":"13","author":"El-Ebidi","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/s1041610203008925","article-title":"Subcortical ischemic vascular disease and dementia.","volume":"15","author":"Erkinjuntti","year":"2003","journal-title":"Int. Psychogeriatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging.","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am. J. Roentgenol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","article-title":"Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease.","volume":"36","author":"Halliday","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1177\/0271678x21990980","article-title":"White matter network damage mediates association between cerebrovascular disease and cognition.","volume":"41","author":"Hilal","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1017\/s1041610210000827","article-title":"Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer\u2019s disease.","volume":"22","author":"Horstmann","year":"2010","journal-title":"Int. Psychogeriatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(19)30290-x","article-title":"Dementia in China: Epidemiology, clinical management, and research advances.","volume":"19","author":"Jia","year":"2020","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000001683","article-title":"Cyclophilin A in Ruptured Intracranial Aneurysm: A Prognostic Biomarker.","volume":"94","author":"Kao","year":"2015","journal-title":"Medicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060503","article-title":"Olfactory Bulb Proteomics Reveals Widespread Proteostatic Disturbances in Mixed Dementia and Guides for Potential Serum Biomarkers to Discriminate Alzheimer Disease and Mixed Dementia Phenotypes.","volume":"11","author":"Lach\u00e9n-Montes","year":"2021","journal-title":"J. Pers. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/jgs.17173","article-title":"White matter hyperintensities and cognition across different Alzheimer\u2019s biomarker profiles.","volume":"69","author":"Lam","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.sleep.2021.10.009","article-title":"Increased serum levels of cyclophilin a and matrix metalloproteinase-9 are associated with cognitive impairment in patients with obstructive sleep apnea.","volume":"93","author":"Li","year":"2021","journal-title":"Sleep Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0197-0186(03)00004-4","article-title":"Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer\u2019s disease.","volume":"43","author":"Lorenzl","year":"2003","journal-title":"Neurochem. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1017\/s1041610207005790","article-title":"Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.","volume":"20","author":"Lorenzl","year":"2008","journal-title":"Int. Psychogeriatr."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-018-0286-0","article-title":"Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-\u03b242 by LRP1-dependent apolipoprotein E isoform-specific mechanism.","volume":"13","author":"Ma","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease.","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus.","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"B36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-021-00073-z","article-title":"APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer\u2019s mice via cyclophilin A independently of amyloid-\u03b2.","volume":"1","author":"Montagne","year":"2021","journal-title":"Nat. Aging"},{"key":"B38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.","volume":"25","author":"Nation","year":"2019","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.bbadis.2015.12.016","article-title":"Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer\u2019s disease.","volume":"1862","author":"Nelson","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00025","article-title":"EEG Spectral Features Discriminate between Alzheimer\u2019s and Vascular Dementia.","volume":"6","author":"Neto","year":"2015","journal-title":"Front. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1084\/jem.20101174","article-title":"Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice.","volume":"208","author":"Nigro","year":"2011","journal-title":"J. Exp. Med."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202207","article-title":"Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A.","volume":"218","author":"Nikolakopoulou","year":"2021","journal-title":"J. Exp. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/s0140-6736(15)00463-8","article-title":"Vascular dementia.","volume":"386","author":"O\u2019Brien","year":"2015","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-1699-6","article-title":"Cyclophilin a signaling induces pericyte-associated blood-brain barrier disruption after subarachnoid hemorrhage.","volume":"17","author":"Pan","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3348\/kjr.2016.17.6.827","article-title":"Structural MR Imaging in the Diagnosis of Alzheimer\u2019s Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives.","volume":"17","author":"Park","year":"2016","journal-title":"Korean J. Radiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"23946","DOI":"10.1074\/jbc.272.38.23946","article-title":"Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma.","volume":"272","author":"Quinn","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-38","article-title":"Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease.","volume":"13","author":"Ramachandran","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/jth.14635","article-title":"Platelet surface expression of cyclophilin A is associated with increased mortality in patients with symptomatic coronary artery disease.","volume":"18","author":"Rath","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/jnr.21324","article-title":"Acutely increased cyclophilin a expression after brain injury: A role in blood-brain barrier function and tissue preservation.","volume":"85","author":"Redell","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0271678x16655551","article-title":"Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.","volume":"36","author":"Rempe","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-beta by circulating lipoprotein receptors.","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/jad-2010-101248","article-title":"Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-\u03b2 is an early biomarker for mild cognitive impairment preceding Alzheimer\u2019s disease.","volume":"24","author":"Sagare","year":"2011","journal-title":"J Alzheimers Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.07.008","article-title":"Low-density lipoprotein receptor-related protein 1: A physiological A\u03b2 homeostatic mechanism with multiple therapeutic opportunities.","volume":"136","author":"Sagare","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1253\/circj.cj-12-0805","article-title":"Plasma cyclophilin A is a novel biomarker for coronary artery disease.","volume":"77","author":"Satoh","year":"2013","journal-title":"Circ. J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/atvbaha.110.214601","article-title":"Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice.","volume":"31","author":"Satoh","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/09537104.2015.1051466","article-title":"Platelet-bound cyclophilin A in patients with stable coronary artery disease and acute myocardial infarction.","volume":"27","author":"Seizer","year":"2016","journal-title":"Platelets"},{"key":"B57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2009.08.029","article-title":"EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.","volume":"209","author":"Seizer","year":"2010","journal-title":"Atherosclerosis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1161\/atvbaha.114.305112","article-title":"Extracellular cyclophilin A activates platelets via EMMPRIN (CD147) and PI3K\/Akt signaling, which promotes platelet adhesion and thrombus formation in vitro and in vivo.","volume":"35","author":"Seizer","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"8296","DOI":"10.1007\/s12035-019-01672-z","article-title":"Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier.","volume":"56","author":"Shackleton","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/jci10498","article-title":"Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.","volume":"106","author":"Shibata","year":"2000","journal-title":"J. Clin. Invest."},{"key":"B61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/jci81108","article-title":"Endothelial LRP1 transports amyloid-\u03b2(1-42) across the blood-brain barrier.","volume":"126","author":"Storck","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B62","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/1533317516653820","article-title":"Vascular Function in Alzheimer\u2019s Disease and Vascular Dementia.","volume":"31","author":"Tachibana","year":"2016","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1172\/jci124853","article-title":"APOE4-mediated amyloid-\u03b2 pathology depends on its neuronal receptor LRP1.","volume":"129","author":"Tachibana","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00080","article-title":"Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia.","volume":"12","author":"Uemura","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102600","article-title":"Disturbance of Intracerebral Fluid Clearance and Blood-Brain Barrier in Vascular Cognitive Impairment.","volume":"20","author":"Ueno","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","article-title":"A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain.","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.13702\/j.1000-0607.1902956","article-title":"[Effect of moxibustion on expression of RAGE and LRP-1 and neuronal ultrastructure of frontal cortex and hippocampus in vascular dementia rats].","volume":"45","author":"Wang","year":"2020","journal-title":"Zhen Ci Yan Jiu"},{"key":"B68","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","article-title":"Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease.","volume":"130","author":"Xiang","year":"2015","journal-title":"Acta Neuropathol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091965","article-title":"Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer\u2019s Disease.","volume":"18","author":"Yamazaki","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.jcbfm.9600375","article-title":"Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.","volume":"27","author":"Yang","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders.","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.949129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:08:47Z","timestamp":1659942527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2022.949129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":71,"alternative-id":["10.3389\/fnins.2022.949129"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2022.949129","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"949129"}}